

Table S1. Sensitivity Analyses Examining Effect of Higher Phosphorus Additive Consumption on Outcomes

	Main Analysis (n=31)		Sensitivity Analysis 1 (n=29)		Sensitivity Analysis 2 (n=25)	
	Estimate (95% CI)	P value	Estimate (95% CI)	P value	Estimate (95% CI)	P value
Albuminuria (mg/d)	14.3% (-2.5%, 34.0%)	0.1	17.3% (0.1%, 37.5%)	0.049	23.7% (4.6%, 46.3%)	0.01
FGF23 (RU/ml)	3.4% (-5.9%, 13.6%)	0.4	2.3% (-7.3%, 12.8%)	0.4	1.0% (-9.6%, 12.9%)	0.9
Intact PTH ¹ (pg/ml)	15.9% (3.8%, 29.5%)	0.01	14.5% (1.8%, 28.7%)	0.02	17.3% (3.3%, 33.3%)	0.01
Serum phosphorus (mg/dL)	-0.10 (-0.29, 0.09)	0.3	-0.11 (-0.32, 0.09)	0.3	-0.08 (-0.32, 0.16)	0.5
SBP (mmHg)	-1.1 (-4.1, 1.9)	0.5	-0.5 (-3.5, 2.6)	0.8	-1.2 (-4.6, 2.1)	0.5
DBP (mmHg)	-0.8 (-2.7, 1.0)	0.4	-0.5 (-2.3, 1.4)	0.6	-1.3 (-3.2, 0.6)	0.2

Sensitivity Analysis 1 excluding non-compliant patients, based on missing product pickups and follow-up visits

Sensitivity Analysis 2 excluding patients suspected to be poorly compliant based on 24-hour urine phosphorus excretion data (<250 mg difference between the higher and lower period)

Abbreviations: FGF23 (fibroblast growth factor 23), PTH (parathyroid hormone), SBP (systolic blood pressure), DBP (diastolic blood pressure)